The FDA has issued more than 200 complete response letters, which detail reasons...
BeOne Medicines has secured approval from the EC for Tevimbra (tislelizumab) to ...
Merck has entered a definitive agreement to acquire biopharmaceutical company Ve...
When it comes to cancer prevention and support, nature offers more help than we ...
Ever feel like your brain isn’t firing on all cylinders? Maybe your memory’s a l...
You wash it, brush it, maybe even style it daily… But lately, your hair just isn...
The FDA has issued more than 200 complete response letters, which detail reasons...
BeOne Medicines has secured approval from the EC for Tevimbra (tislelizumab) to ...
As the global population accelerates towards nearly 10 billion by mid-century, t...
In the dynamic arena of drug discovery, high-content image-based phenotypic scre...
In the ever-evolving landscape of botanical research, the intricate architecture...
In a groundbreaking cohort study emerging from China, researchers have explored ...
AstraZeneca’s rare disease division, Alexion, has finalized a license agreement ...
The benefit-risk ratio looks like it increasingly favours Eli Lilly’s Kisunla in...
Alcon has announced its plan to acquire LumiThera, Inc., a company that develope...
A new center dedicated to advancing CRISPR-based treatments for severe genetic c...
Merck has entered a definitive agreement to acquire biopharmaceutical company Ve...
Zentiva Group has entered a licence and supply agreement with Lupin for the comm...
